bemiparin

01/01/2009 - "Both groups of treated patients showed low incidence rates of thromboses and we did not see a significant reduction of incidence rates with higher dosages of bemiparin in this population. "
04/01/2003 - "Fifty-two per cent of patients in group A, 72% of group B and 72% of group C showed venographic reduction in thrombus size assessed objectively on day 14; 20% greater improvement in group B and C indicates not only non-inferiority of bemiparin (p = 0.00003) but also superiority (p = 0.004) compared to UFH. "
12/14/2010 - "A case report describing the treatment of a neonate with renal vein thrombosis showed that 2 months' treatment with bemiparin followed by 10 months' prophylaxis was effective and safe. "
01/01/2009 - "This study asks whether present-day obese patients would benefit from higher than usual dosages of bemiparin in the prophylaxis of postoperative thrombosis. "
09/01/2003 - "In patients with acute DVT, bemiparin was more effective than UFH in thrombus mass reduction and at least as effective as UFH for the prevention of clinical recurrence. "

12/14/2010 - "Subcutaneous bemiparin has been evaluated for the prevention of venous thromboembolism (VTE) in moderate to high-risk patients undergoing surgery, and for the acute and long-term treatment of established VTE. "
12/14/2010 - "A decade of contribution to therapeutic progress: bemiparin in the management of venous thromboembolism. "
06/01/2006 - "Outpatient management of venous thromboembolism with bemiparin in selected patients resulted in significant cost savings compared with in-patient treatment, while maintaining effectiveness and safety. "
06/01/2006 - "Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism."
09/01/2003 - "Bemiparin 2500 IU/day was as effective as UFH for preventing venous thromboembolism (VTE) in moderate risk abdominal surgery. "

05/01/2010 - "Interestingly, recent results suggest that bemiparin could be useful as an adjuvant treatment in the management of lower-extremity diabetic ulcers. "
09/01/2008 - "Ulcer improvement rates were 70.3% (26 of 37 patients) in the bemiparin group and 45.5% (15 of 33 patients) in the placebo group [absolute difference 24.8; 95% confidence interval (CI) 2.3, 47.3; P = 0.035] (number needed to treat 4; 95% CI 2, 43). "
09/01/2008 - "Bemiparin 3500 IU/day for 10 days, followed by 2500 IU/day for up to 3 months plus standard care for ulcers, was compared with placebo plus standard care for ulcers for 3 months. "
09/01/2008 - "Bemiparin is more effective than placebo in the management of diabetic foot ulcers and has few side-effects."
05/15/2003 - "To establish the degree of efficacy of bemiparin treatment over 3 months in the improvement of slow-responding ulcers in diabetic foot. "

09/01/2008 - "Bemiparin is more effective than placebo in the management of diabetic foot ulcers and has few side-effects."
05/15/2003 - "To establish the degree of efficacy of bemiparin treatment over 3 months in the improvement of slow-responding ulcers in diabetic foot. "
07/01/2014 - "Recent evidences suggested the application of bemiparin even in the management of diabetic foot ulcers. "
03/01/2009 - "Authors' response to 'Comments on the use of bemiparin in diabetic foot ulcers'."
01/01/2009 - "Comments on the use of bemiparin in diabetic foot ulcers."

04/01/2020 - "Bemiparin is effective and safe for the long-term treatment of cancer-associated VTE in routine clinical practice."
04/01/2020 - "There have been no specific studies evaluating bemiparin for VTE in people with cancer. "
07/10/2016 - "The aim of the study is to investigate anti-cancer mechanism of bemiparin in HepG2 and Mia-Paca-2 cancer cells. "
08/01/2020 - "This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. "
04/01/2020 - "Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited. "